Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Provention Bio

Biotech & Life Sciences · Lebanon, United States · Founded 2016 · IPO 2018 Unicorn

Clinical stage biopharmaceutical dedicated to sourcing, developing and commercializing novel therapeutics

Valuation
$2.16B
Market cap · 2026
Revenue
$13M
Latest reported FY

Investors

3 investors on Provention Bio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage
JDRF T1D Fund
MDB Capital Group
Johnson & Johnson Innovation

Global footprint

Where Provention Bio has talent and traffic

Workforce by country
🇺🇸 United States · Lebanon HQ
Book a demo for the full country breakdown
Web traffic by country
80 monthly visits
across markets
🇬🇧 United Kingdom125%
Top 1 markets shown

Patent intelligence

$4M patent portfolio · 22 active families

Estimated portfolio value
$4M
0.19% of market cap · 128.3× smaller than top peer ChemoCentryx ($524M)
22 active patent families
Where Provention Bio innovates CD3 AntibodyPharmacologyType 1 diabetesClinical typeAntiendomysial antibodies

Where Provention Bio concentrates vs peers

Each axis is a top-10 topic across Provention Bio and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Provention Bio

An AI-synthesized read of the highest-engagement posts about Provention Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Provention Bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.